In the News
Beginning a New Era of Precision Alzheimer’s Therapeutics
Inside Precision Medicine
Newsweek Investment Report: Interview with Dr. Martin Tolar, President & CEO of Alzheon, Inc. January 2024
Newsweek Investment Reports
ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’s
Alzheimer's News Today
Press Releases
New Peer-Reviewed Scientific Publication Describes Study Design and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease
APOLLOE4 is the first interventional AD drug trial focused on APOE4/4 homozygotes, a population enriched with amyloid pathology in brain parenchyma and small vessels – a condition called cerebral amyloid angiopathy
Alzheon to Present Phase 2 Biomarker Trial Results and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in Patients with Early Alzheimer’s Disease at Alzheimer’s Association International Conference
Fully Enrolled Pivotal APOLLOE4 Phase 3 Trial in Early Alzheimer’s Patients on Track for Topline Data Readout in 2024
Two Peer-Reviewed Scientific Publications Describe Fluid Biomarker, Brain Preservation and Clinical Benefits Following 2 Years of Treatment in Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease
Early, Sustained and Statistically Significant Reduction in Plasma P-tau181 Reaching 31% at 24 Months Observed in Carriers of One or Two Copies of APOE4 Gene, who Represent Two Thirds of Alzheimer’s Patients
Alzheon Raises $100 Million Series E Financing Round to Advance Development and Commercialization of Oral Tablet ALZ-801/Valiltramiprosate for Treatment of Alzheimer’s Disease
Proceeds Will Support Completion of Pivotal APOLLOE4 Phase 3 Study Evaluating ALZ-801/Valiltramiprosate and Regulatory Filings for Patients with Early Alzheimer’s Disease in 2024
Alzheon Announces Appointment of Renowned Biopharma Executive Gino Santini to Board of Directors
Mr. Santini’s Extensive Global Commercial and Business Development Experience Strengthens Alzheon’s Board Leadership
Alzheon Announces First Patient Dosed in Long-Term Extension of APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate and Launches 52-Week Extension of Phase 2 Biomarker Trial in Patients with Early Alzheimer’s Disease
APOLLOE4 Phase 3 Trial Subjects Who Completed 78 Weeks of Treatment Offered Enrollment in Long-Term Extension Study to Provide Insights into Effect of ALZ-801